Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Investors Are Buzzing About These 5 Stocks Today

Page 1 of 2

The U.S stock market seems to have put Brexit fears behind it, with the main indices setting new record highs today. Japanese Prime Minister Shinzo Abe’s pledge to further stimulate that country’s economy has also spurred investors to drive the market higher. In this article we’ll take a look at some of the stocks that have followed the main trend but also a couple that are deep in the red today as the second quarter earnings season kicks into full gear.

Our backtests that covered the period between 1999 and 2012, showed that following the 15 most popular small-caps among hedge funds can help a retail investor beat the market by an average of 95 basis points per month (see more details here).

stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart

crystal51/Shutterstock.com

Study Fail Leads to 60% Plunge 

Shares of CytRx Corporation (NASDAQ:CYTR) have plummeted by more than 60% this morning after one of its drugs failed a late-stage study. The stock is currently trading around the $0.85 level, heavily down from yesterday’s closing price of $2.51 per share. The company said its drug candidate aldoxorubicin did not show a significant improvement over doxorubicin, the classic chemotherapy drug, among patients suffering from soft tissue sarcoma. CytRx Corporation (NASDAQ:CYTR) said it hopes to conduct a second analysis, as half of the patients included in the study were excluded from the data because of an interruption of the study in November 2014. At the end of March, roughly 12% of CytRx Corporation (NASDAQ:CYTR)’s common stock was held by eight of the hedge funds in Insider Monkey’s database.

Follow Cytrx Corp (NASDAQ:CYTR)
Trade (NASDAQ:CYTR) Now!

Market Speculation?

Manhattan Associates, Inc. (NASDAQ:MANH), an application software company, has seen its stock plunge by more than 7% during the first hours of trading, apparently due to technical trading. So far this year, the stock has been a steady performer, trending sideways since it managed to regain the ground that it lost amid the broader market sell off in the beginning of the year. Manhattan Associates, Inc. (NASDAQ:MANH) is scheduled to release its second quarter results on July 19 after the closing bell, with analysts predicting earnings of $0.44 per share on the back of $153 million in revenue. Shares are currently trading at a Price-to-Earnings (P/E) multiple of 42, lower than the industry average of 54, per Yahoo! Finance data.

The popularity of Manhattan Associates, Inc. (NASDAQ:MANH) among the funds that we track cooled down during the first three months of 2016, with the number of long positions among those hedge funds having dropped to 21 from 23.

Follow Manhattan Associates Inc (NASDAQ:MANH)
Trade (NASDAQ:MANH) Now!

Head to the next page to read about three more market movers.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!